Glofitamab plus chemotherapy meets OS end point in R/R DLBCL

The phase 3 STARGLO study recently met its primary endpoint, as treatment with the bispecific CD20-directed CD3 T-cell engager glofitamab plus gemcitabine and oxaliplatin led to a statistically significant improvement in overall survival (OS) vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL who had received at least 1 prior line of therapy and were not eligible for autologous stem cell transplant.